

**MEDNAX, INC.**  
**RECONCILIATION OF INCOME FROM CONTINUING OPERATIONS**  
**TO ADJUSTED EBITDA FROM CONTINUING OPERATIONS ATTRIBUTABLE TO MEDNAX, INC.**  
(in thousands)  
(Unaudited)

	<b>2021</b>				
	<b>Three Months Ended March 31, 2021</b>	<b>Three Months Ended June 30, 2021</b>	<b>Three Months Ended September 30, 2021</b>	<b>Three Months Ended December 31, 2021</b>	<b>Twelve Months Ended December 31, 2021</b>
Income from continuing operations attributable to Mednax, Inc.	\$ 5,352	\$ 30,533	\$ 31,847	\$ 40,282	\$ 108,014
Interest expense	17,645	16,879	17,595	16,603	68,722
Gain on sale of building	-	(7,280)	-	-	(7,280)
Loss on early extinguishment of debt	14,532	-	-	-	14,532
Income tax (benefit) provision	(4,955)	7,363	11,594	13,239	27,241
Depreciation and amortization expense	8,031	8,106	8,151	7,859	32,147
Transformational and restructuring related expenses	4,878	9,932	4,232	3,058	22,100
Adjusted EBITDA from continuing operations attributable to Mednax, Inc.	<u>\$ 45,483</u>	<u>\$ 65,533</u>	<u>\$ 73,419</u>	<u>\$ 81,041</u>	<u>\$ 265,476</u>